Article
MK-0457, an Aurora kinase and BCR-ABL inhibitor, is active in patients with BCR-ABL T315I leukemia.
Leukemia - 1 Jan 2013
Giles F J, Swords R T, Nagler A, Hochhaus A, Ottmann O G, Rizzieri D A, Talpaz M, Clark J, Watson P, Xiao A, Zhao B, Bergstrom D, Le Coutre P D, Freedman S J, Cortes J E
Abstract excerpt
MK-0457, an Aurora kinase and BCR-ABL inhibitor, was studied on a Phase I/II study in 77 patients with refractory hematologic malignancies. The average number of cycles per patient was 3 (range 1-21). Maximum tolerated doses for a 5-day short infusion and continuous infusion regimens were 40 mg/m(2)/h and 144 mg/m(2)/h, respectively. Drug-related adverse events (AEs) included transient mucositis and alopecia....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.